Zoetis Inc. (ZTS): Price and Financial Metrics
Zoetis Inc. (ZTS)
Today's Latest Price: $140.16 USD
0.92 (0.66%)
Updated Jan 17 12:00am
Add ZTS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 213 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
ZTS Stock Summary
- Zoetis Inc's market capitalization of $65,986,498,095 is ahead of 96.8% of US-listed equities.
- With a one year PEG ratio of 826.87, Zoetis Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 94.59% of US stocks.
- Price to trailing twelve month operating cash flow for ZTS is currently 36.72, higher than 89.45% of US stocks with positive operating cash flow.
- If you're looking for stocks that are quantitatively similar to Zoetis Inc, a group of peers worth examining would be BSX, CAT, DE, ABB, and BDX.
- ZTS's SEC filings can be seen here. And to visit Zoetis Inc's official web site, go to www.zoetis.com.
ZTS Daily Price Range
ZTS 52-Week Price Range
ZTS Stock Price Chart More Charts
ZTS Price/Volume Stats
| Current price | $140.16 | 52-week high | $140.40 |
| Prev. close | $139.24 | 52-week low | $82.80 |
| Day low | $138.86 | Volume | 1,993,100 |
| Day high | $140.40 | Avg. volume | 1,734,592 |
| 50-day MA | $126.31 | Dividend yield | 0.57% |
| 200-day MA | $118.00 | Market Cap | 66.76B |
Zoetis Inc. (ZTS) Company Bio
Zoetis Inc. discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. The company was founded in 1952 and is based in Florham Park, New Jersey.
Top Stories View All
Best & Worst Performing Stock Industries for January 20, 2020
Best & Worst Performing Small Cap Stocks for January 20, 2020
Best & Worst Performing Mid Cap Stocks for January 20, 2020
Best & Worst Performing Large Cap Stocks for January 20, 2020
Best & Worst Performing Mega Cap Stocks for January 20, 2020
View All Top Stories
Loading social stream, please wait...